Literature DB >> 2400574

Synthesis of cysteine proteinase inhibitors structurally based on the proteinase interacting N-terminal region of human cystatin C.

A Grubb1, M Abrahamson, I Olafsson, J Trojnar, R Kasprzykowska, F Kasprzykowski, Z Grzonka.   

Abstract

Peptides spanning the entire, or part of, the Gly4-Glu21 segment of the human cysteine proteinase inhibitor cystatin C have been synthesized. Peptides containing residues on the N-terminal side of Gly11 were rapidly cleaved by papain at the bond Gly11-Gly12 whereas a peptide starting at residue Gly11 was not, thus demonstrating 1. that the N-terminal segment of cystatin C has an amino acid sequence that would allow rapid interaction between this segment and the substrate pocket of papain and, if this interaction takes place, that 2. the cystatin C residue Gly11 would be in the P1 position, and 3. the major interaction would be between residues Arg8-Val10 and the papain substrate pocket subsites S4, S3 and S2, respectively. Several modified peptide derivatives containing either diazomethane groups or peptide bond isosters were synthesized based on the structure of the Leu9-Gly11 segment of cystatin C and tested for their cysteine proteinase inhibiting capacity. The peptidyl derivatives, t-butyloxycarbonyl-valyl-glycyl-diazomethane and benzyloxycarbonyl-leucyl-valyl-glycyl-diazomethane irreversible inhibited the cysteine proteinases papain, bovine cathepsin B and streptococcal proteinase, but did not influence the activity of serine, aspartic or metallo-proteinases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400574

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  8 in total

Review 1.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Authors:  Yanwen Qin; Guo-Ping Shi
Journal:  Pharmacol Ther       Date:  2011-05-12       Impact factor: 12.310

2.  Conserved cystatin segments as models for designing specific substrates and inhibitors of cysteine proteinases.

Authors:  G Lalmanach; C Serveau; M Brillard-Bourdet; J R Chagas; R Mayer; L Juliano; F Gauthier
Journal:  J Protein Chem       Date:  1995-11

3.  Inhibitory effects of recombinant human cystatin C on human coronaviruses.

Authors:  A R Collins; A Grubb
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  MNDO study of the mechanism of the inhibition of cysteine proteinases by diazomethyl ketones.

Authors:  M Tarnowska; S Oldziej; A Liwo; P Kania; F Kasprzykowski; Z Grzonka
Journal:  Eur Biophys J       Date:  1992       Impact factor: 1.733

5.  Interaction between cystatin-derived peptides and papain.

Authors:  G Lalmanach; J Hoebeke; T Moreau; M Brillard-Bourdet; M Ferrer-Ditt Martino; F Borras-Cuesta; F Gauthier
Journal:  J Protein Chem       Date:  1993-02

6.  Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase.

Authors:  M Abrahamson; R W Mason; H Hansson; D J Buttle; A Grubb; K Ohlsson
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

Review 7.  Cystatin C--properties and use as diagnostic marker.

Authors:  A O Grubb
Journal:  Adv Clin Chem       Date:  2000       Impact factor: 5.394

8.  Design, synthesis, evaluation and thermodynamics of 1-substituted pyridylimidazo[1,5-a]pyridine derivatives as cysteine protease inhibitors.

Authors:  Mohd Sajid Khan; Mohd Hassan Baig; Saheem Ahmad; Shapi Ahmad Siddiqui; Ashwini Kumar Srivastava; Kumar Venkatraman Srinivasan; Irfan A Ansari
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.